- TheStreet.com•last year
Neostem (NBS) shares are falling after the company priced is secondary offering below its previous closing price.
- Benzinga•last year
NeoStem Inc (NASDAQ: NBS ) recently received a grant of $17.7 million to fund the company's effort in research of cell therapy products for cancer from California Institute of Regenerative Medicine. Following ...
We're sorry this is all we were able to find about this topic.
NasdaqCM . Currency in USD
|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52wk Range||undefined - undefined|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||N/A|
|Dividend & Yield||N/A (N/A)|